UNSPSC 51151655: Otenzepad

This classification denotes an antimuscarinic agent with the molecular formula C24H31N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OM7J0XAL0S, chemically known as 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((2-((diethylamino)methyl)-7-piperidinyl)acetyl)- but generally known as otenzepad, which bears US NIH Compound Identifier 107867. European Medicines Agency schedules Otenzepad in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09478MIG.

UNSPSC 51151655 Otenzepad is a Commodity code that captures state and local procurement of naloxone and related opioid-response pharmaceuticals and drug deactivation systems. State and local governments soliciting under this code include county health departments and state health agencies pursuing community health initiatives and substance-abuse response programs. Seminole County, Florida, for example, is procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding to support community health initiatives, with quarterly deliveries to a designated county health facility. The Texas Health and Human Services Commission has issued a Request for Information to explore direct-to-manufacturer prescription models for therapeutic pharmacy programs. Vendors responding to solicitations under this code must typically meet E-Verify compliance, drug-free workplace certification, and relevant insurance requirements, including workers' compensation and commercial general liability coverage. Contracts often include multi-year initial terms with optional renewals and fixed-fee pricing structures.

Recent activity under the code appears concentrated in Florida and Texas. Seminole County's IFB (IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, represents direct procurement of naloxone and deactivation systems with defined annual volumes and quarterly delivery schedules. The Texas HHS Commission RFI (HHS0017013), posted April 3, 2026, signals exploratory procurement activity around direct-to-manufacturer prescription fulfillment models but does not indicate an imminent formal solicitation or defined contract values. The Seminole County opportunity shows concrete demand for naloxone supply chains in the public health sector; the Texas RFI indicates state-level interest in reshaping pharmacy benefit program structures but remains in early information-gathering stages.